Zhejiang Jingxin Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001K73
CNY
15.05
0.03 (0.2%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Net Sales
4,045.83
4,136.43
3,977.49
3,757.57
3,447.09
3,236.37
3,618.90
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
4,045.83
4,136.43
3,977.49
3,757.57
3,447.09
3,236.37
3,618.90
Raw Material Cost
2,104.76
2,162.09
2,048.32
1,857.10
1,629.55
1,354.75
1,329.73
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
6.29
9.73
9.88
7.75
6.71
7.68
12.40
Selling and Distribution Expenses
783.35
883.34
959.15
933.22
948.07
1,139.65
1,560.24
Other Expenses
33.32
34.39
36.19
31.91
28.26
20.82
21.67
Total Expenditure (Excl Depreciation)
3,227.63
3,399.08
3,379.26
3,117.20
2,866.98
2,710.28
3,119.08
Operating Profit (PBDIT) excl Other Income
818.1999999999999
737.4
598.2
640.4000000000001
580.1
526.1
499.79999999999995
Other Income
106.13
182.21
118.96
132.97
143.33
126.50
131.21
Operating Profit (PBDIT)
1,166.71
1,205.33
919.61
951.29
893.92
795.91
726.37
Interest
6.29
9.73
9.88
7.75
6.71
7.68
12.40
Exceptional Items
-4.37
-40.19
25.82
10.89
-0.90
131.41
-0.10
Gross Profit (PBDT)
1,941.06
1,974.34
1,929.18
1,900.47
1,817.54
1,881.62
2,289.17
Depreciation
291.25
310.77
221.47
199.95
182.53
154.42
115.31
Profit Before Tax
864.80
844.64
714.08
754.48
703.79
765.21
598.56
Tax
97.66
124.85
84.62
82.49
81.57
105.65
81.47
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
757.98
711.96
618.90
662.25
612.54
653.07
520.40
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
757.98
711.96
618.90
662.25
612.54
653.07
520.40
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
8.69
7.16
4.52
5.57
5.42
0.26
1.55
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
766.67
719.13
623.42
667.82
617.96
653.33
521.95
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
5,833.04
5,969.51
5,512.37
5,146.12
4,861.54
3,917.60
3,696.08
Earnings per share (EPS)
0.92
0.83
0.72
0.77
0.75
0.83
0.64
Diluted Earnings per share
0.92
0.83
0.72
0.77
0.75
0.83
0.64
Operating Profit Margin (Excl OI)
19.02%
17.22%
14.56%
16.46%
16.48%
15.91%
13.26%
Gross Profit Margin
28.57%
27.93%
23.52%
25.4%
25.71%
28.42%
19.73%
PAT Margin
18.73%
17.21%
15.56%
17.62%
17.77%
20.18%
14.38%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2025 is -2.19% vs 3.99% in Dec 2024

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2025 is 6.62% vs 15.35% in Dec 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2025 is 3.67% vs 27.78% in Dec 2024

stock-summary

Interest

YoY Growth in year ended Dec 2025 is -35.05% vs -2.02% in Dec 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2025 has improved from Dec 2024

Compare Annual Results Of Zhejiang Jingxin Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
4,045.83
0
4,045.83
Other Operating Income
0.00
0.00
0.00
Total Operating income
4,045.83
0
4,045.83
Raw Material Cost
2,104.76
0
2,104.76
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
6.29
0
6.29
Selling and Distribution Expenses
783.35
0
783.35
Other Expenses
33.32
0.00
33.32
Total Expenditure (Excl Depreciation)
3,227.63
0
3,227.63
Operating Profit (PBDIT) excl Other Income
818.19
0.00
818.19
Other Income
106.13
0
106.13
Operating Profit (PBDIT)
1,166.71
0
1,166.71
Interest
6.29
0
6.29
Exceptional Items
-4.37
0
-4.37
Gross Profit (PBDT)
1,941.06
0
1,941.06
Depreciation
291.25
0
291.25
Profit Before Tax
864.80
0
864.80
Tax
97.66
0
97.66
Provisions and contingencies
0
0
0.00
Profit After Tax
757.98
0
757.98
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
757.98
0
757.98
Share in Profit of Associates
0
0
0.00
Minority Interest
8.69
0
8.69
Other related items
0.00
0.00
0.00
Consolidated Net Profit
766.67
0
766.67
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
5,833.04
0
5,833.04
Earnings per share (EPS)
0.92
0
0.92
Diluted Earnings per share
0.92
0
0.92
Operating Profit Margin (Excl OI)
19.02%
0%
0.00
19.02%
Gross Profit Margin
28.57%
0%
0.00
28.57%
PAT Margin
18.73%
0%
0.00
18.73%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 404.58 Million
in Dec 2025

Figures in Million
stock-summary

YoY Growth in year ended Dec 2025 is -2.19% vs 3.99% in Dec 2024

Annual - Consolidate Net Profit
Consolidate Net Profit 76.67 Million
in Dec 2025

Figures in Million
stock-summary

YoY Growth in year ended Dec 2025 is 6.62% vs 15.35% in Dec 2024

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 106.06 Million
in Dec 2025

Figures in Million
stock-summary

YoY Growth in year ended Dec 2025 is 3.67% vs 27.78% in Dec 2024

Annual - Interest
Interest 0.63 Million
in Dec 2025

Figures in Million
stock-summary

YoY Growth in year ended Dec 2025 is -35.05% vs -2.02% in Dec 2024

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 19.02%
in Dec 2025

Figures in %
stock-summary

YoY Growth in year ended Dec 2025 has improved from Dec 2024